Mass cytometry papers in blood cancers from 2020
You will find the list of papers of mass cytometry (CyTOF) in blood cancers in 2020.
It might help you to review the work already done in the field this year.
If you are more interested in solid cancers, you can visit our dedicated webpage on solid cancers investigated by mass cytometry. We started to follow COVID19-related mass cytometry studies.




07-Jan-2021
Marcel Doerflinger
Materials
17 patients
Number of markers
17 markers
Patients with multiple myeloma are more susceptible to infections. Authors conducted mass cytometry research to identify predictive markers for infection. No detection of phenotypic or numerical differences in immune cell populations between patients that did and did not develop infections. Transcriptional profiling of stimulated PBMCs revealed distinct Th2 immune pathway signatures in patients that developed infection.
Successful identification of predictive profiles for infection utilising systems‐level immune analysis: a pilot study in patients with relapsed and refractory multiple myeloma
Clinical and Translational Immunology
13-Oct-2020
Slavica Vuckovic
Materials
PB of 4 MGUS 8 NDMM
Number of markers
37 markers
Analysis of CD8+CD57+ terminal effector T cells in the bone marrow and peripheral blood of age-matched controls and patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), and newly diagnosed (ND) MM
Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients
Blood advances
23-Aug-2020
Fathima Zumla Cader
Materials
7 patients Hodgkin disease and 10 patients without malignant disease (but lymphoid hyperplasia).
Number of markers
39 markers
Comparison between Hodgkin lymphoma biopsies and control reactive lymph node/tonsil samples. In Hodgkin lymphoma: expression of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs).
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment
Blood
21-Aug-2020
Melissa M. Berrien-Elliott,
Materials
1 patient or in vitro cells
Number of markers
37 markers
Study of NK cell therapy in leukemia patients. NKG2A is a dominant, transcriptionally-induced checkpoint important for ML, but not conventional NK cell responses to cancer. The frequency of CD8a+ donor NK cells is negatively associated with AML patient outcomes after ML NK therapy
Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia
Cancer discovery
10-Aug-2020
Fathima Zumla Cader
Materials
56 patients
Number of markers
39 markers
Study of the peripheral immune signature of responsiveness to PD-1 blockade in 56 patients treated in the CheckMate 205 phase II clinical trial. CD4+, but not CD8+, TCR diversity significantly increased during therapy, most strikingly in patients who had achieved complete responses. Responders show a newly identified CD3−CD68+CD4+GrB+ subset and activated NK cell subset.
A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma
Nature Medicine
22-July-2020
Gautam Borthakur
Materials
2 patients
Number of markers
Non available
Phase I trial involving sorafenib, plerixafor and G-CSF
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients
Hematology
21-July-2020
Jithendra Kini Bailur
Materials
36 B cell acute lymphoblastic leukemia, 28 acute myeloid leukemia, 11 healthy donors
Number of markers
37 markers
Combination of mass cytometry, single cell genomics, and functional studies to characterize the BM immune environment in children with B cell acute lymphoblastic leukemia and acute myelogenous leukemia at presentation
Risk-associated alterations in marrow T cells in pediatric leukemia
JCI Insight
22-Jul-2020
Gautam Borthakur
Materials
2 patients analyzed by CyTOF
Number of markers
30 markers
Mass cytometry analysis of sequential samples from two patients demonstrated resistance emerging early on from sub‐clones with persistent Akt and/or ERK signaling
Phase 1 Study of combinatorial sorafenib, G‐CSF , and plerixafor treatment in relapsed/refractory, FLT3‐ITD ‐mutated acute myelogenous leukemia patients
American Journal of Hematology
20-Jul-2020
Edit Kotogány
Materials
2 patients
Number of markers
15 markers
Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative drug candidate on human
patient-derived AML cells showed an increase of CD11b and decrease of CD33+, CD7+, CD206+,
and CD38bright cells followed apoptosis after treatment ex vivo.
Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of
Immature Myeloid Cells Such as Acute Myeloid
Leukemia and Myeloid-Derived Suppressor Cells
International Journal of Molecular Sciences
21-Jul-20
Jithendra Kini Bailur
Materials
64 patients
Number of markers
37 markers
Characterization the bone marrow immune environment in children with B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia at presentation. T cells in leukemia marrow demonstrate evidence of chronic immune activation and exhaustion/dysfunction, , with attrition of naïve T cells and TCF1+ stem-like memory T cells and accumulation of terminally-differentiated effector T cells.
Risk associated alterations in marrow T cells in pediatric leukemia
JCI Insight
30-Jun-20
Zhi-Zhang Yang
Materials
82 follicular lymphoma patients
Number of markers
37 markers
Mass cytometry shows that TIGIT is highly expressed on intratumoral T cells and its expression alters T cell phenotype in Follicular Lymphoma. Increased numbers of TIGIT+ T cells are associated with inferior patient outcomes and poor survival.
TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma
Clinical Cancer Research
05-Jun-20
Srividya Swaminathan
Materials
Lymphoma murine cancer model and human human cells
Number of markers
Mouse 15 markers / human: 32 markers
Systemic reduction in natural killer (NK) cell numbers in SRα-tTA/Tet-O-MYCON mice bearing MYC-driven T-lymphomas. CyTOF provided a rationale for developing NK cell-based therapies to effectively treat MYC-driven lymphomas in the future.
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies
Nature Communications
26-May-20
Tineke Casneuf
Materials
149 patient samples and 38 control samples
Number of markers
37 markers
Daratumumab’s effects on immune cells in whole blood samples of relapsed/refractory Multiple Myeloma patients from both treatment arms (lenalidomide/dexamethasone or daratumumab plus Rd) at baseline and after 2 months on treatment using mass cytometry. CyTOF showed NK cell reduction with Daratumumab-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to Daratumumab-Rd, with a higher proportion of CD8+ versus CD4+ T cells.
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
Leukemia
15-May-20
Abhishek A. Mangaonkar,
Materials
7 chronic myelomonocytic leukemia (CMML) patients and 3 controls
Number of markers
30 markers
Aggregate IDO1+ dendritic cell populations occur in the chronic myelomonocytic leukemia bone marrow microenvironment, and their presence correlates with disease progression.
Indoleamine 2,3-dioxygenase-1 expressing aggregate bone marrow dendritic cell populations are associated with systemic T-cell compartment changes in chronic myelomonocytic leukemia
bioRXiiv
12-May-20
Tamara Davenne
Materials
14 patients with CLL
Number of markers
28 markers
Mass cytometry finds that deoxyguanosine and forodesine kill SAMHD1-deficient malignant cells in patients with chronic lymphocytic leukemia (CLL). Normal cells and CLL cells from patients without SAMHD1 mutation are unaffected by treatment. CyTOF could distinguish between all populations.
SAMHD1 Limits the Efficacy of Forodesine in
Leukemia by Protecting Cells against the
Cytotoxicity of dGTP
Cell Reports
01-May-20
Manman Denga
Materials
18 AML patients
Number of markers
8 markers
VEGF/VEGFRs correlates with chemotherapy resistance in AML
VEGF/VEGFRs correlates with poor clinical outcome in AML
Apatinib exhibits cytotoxicity toward leukemia cells by targeting VEGFR2-mediated prosurvival signaling and angiogenesis
Experimental Cell Research
29-Apr-20
Jinheng Wang
Materials
5 Healthy BM versus 10 MM BM
Number of markers
30 markers
Masss cytometry revealed an increase in activated CD4 T, CD8 T, CD8+ natural killer T‐like and NK cells in Multiple Myeloma in Bone Marrow
Identification of the immune checkpoint signature of multiple myeloma using mass cytometry‐based single‐cell analysis
Clinical & Translational Immunology
21-Apr-20
Adam J. Lamble
Materials
Bone marrow and peripheral blood samples from patients with newly diagnosed AML
Number of markers
2 panels: 35, 34
Association between T cell infiltration in the bone marrow microenvironment of newly diagnosed patients with AML and increased overall survival.
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia
PNAS
11-Feb-20
Palash C. Maity
Materials
nonstereotypic CLL samples and analyzed B cells isolated from 5 healthy donors (HDs) as control.
Number of markers
23 markers
Healthy B cell isolates were limited to 3 major phenotypically discrete clusters, CLL samples allocated 14 independent phenotypic clusters. Mutated CLL cells were phenotypically different from unmutated CLL cells and shared only 1 phenotypic cluster.
IGLV3-21*01 is an inherited risk factor for (chronic lymphocytic leukemia) CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
PNAS
27-Jan-20
Charis E Teh
Materials
M.1S, OPM2, AMO1, U266, KMS-12-BM, or H929 cells
Number of markers
26 markers
Treatment of myeloma cells with dexamethasone or bortezomib and the authors studied the effect of the treatment with mass cytometry. Increased amounts of phosphorylated cAMP and the pro-survival protein MCL-1 were defining features of cells surviving drug treatment. CyTOF analysis of patient bone marrow cells identified myeloma cells and their key cell survival features.
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells
Cell Death & Differentiation
09-Jan-20
Mikael Roussel
Materials
22 tissues samples were analyzed, from 16 lymphoma patients and 6 control samples
Number of markers
35 markers
Mass cytometry proves that CD163, CD68, S100A9, CCR2, CD36, Slan, and CD32 should be measured to effectively characterize lymphoma-specific tumor macrophages
Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas
Cancer Immunology, Immunotherapy
19-Dec-19
Aoki, T et al.
Materials
22 Hodgkin lymphoma tissue specimens and 5 reactive lymph nodes, validation with 166 patients
Number of markers
Not accessible
Identification of novel Hodgkin lymphoma: mass cytometry highlited an association with a subset of LAG3+ T cells
Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma
Cancer Discovery
29-Nov-2020
Astrid Tschan-Plessl
Materials
10 patients
Number of markers
36 markers
Investigate the feasibility and safety of haploidentical natural killer (NK) cell infusions as consolidation immunotherapy. Multiparametric mass cytometry analysis demonstrated an altered surface receptor repertoire of expanded NK cells with increased degranulation and cytokine production activities but diminished expression of perforin.
Cellular immunotherapy with multiple infusions of in vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell myeloma
Cytotherapy
2-July-2020
Leandro Venturutti
Materials
Mice
Number of markers
Intra and extracellular marker
TBL1XR1 mutation skews the humoral immune response toward producing memory B cells.
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate
Cell
23-July-2020
Kim A Reiss
Materials
15 patients
Number of markers
37 markers
Administration of TGF-β inhibitor with stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC). Study of the blood. Treatment with galunisertib was associated with a decrease in the frequency of activated T regulatory cells in the blood. Non-progressors also had increased CD8+PD-1+TIGIT+ T cells in the blood after treatment.
A Pilot Study of Galunisertib Plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
Molecular Cancer Therapeutics
14-Sept-2020
William E. Pierceall1
Materials
6 patients
Number of markers
39 markers
Study of combination treatment f daratumumab to pomalidomide and lowdose dexamethasone. Immunophenotypic changes were analyzed in peripheral blood.
Immunomodulation in Pomalidomide, Dexamethasone,
and Daratumumab-Treated Patients with Relapsed/
Refractory Multiple Myeloma
Clinical Cancer Research
Materials
Number of markers